Hyperfine (HYPR) to Post Earnings on Thursday

Hyperfine (NASDAQ:HYPR) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Hyperfine to post earnings of ($0.09) per share and revenue of $4.1350 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Hyperfine (NASDAQ:HYPR) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Hyperfine had a negative net margin of 226.88% and a negative return on equity of 98.83%. The firm had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.54 million.

Hyperfine Trading Down 2.7%

NASDAQ:HYPR opened at $0.89 on Thursday. Hyperfine has a 52 week low of $0.85 and a 52 week high of $2.22. The firm has a 50 day moving average of $1.31 and a 200 day moving average of $1.26. The company has a quick ratio of 4.90, a current ratio of 5.52 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $88.45 million, a price-to-earnings ratio of -2.17 and a beta of 1.40.

Institutional Investors Weigh In On Hyperfine

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in Hyperfine by 674.4% in the 4th quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock worth $357,000 after purchasing an additional 317,645 shares during the period. Vanguard Group Inc. grew its holdings in Hyperfine by 5.7% in the third quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock valued at $5,092,000 after purchasing an additional 190,136 shares during the period. Geode Capital Management LLC increased its position in shares of Hyperfine by 21.4% in the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock valued at $799,000 after buying an additional 143,975 shares in the last quarter. State Street Corp raised its stake in shares of Hyperfine by 6.1% during the 4th quarter. State Street Corp now owns 265,195 shares of the company’s stock worth $260,000 after buying an additional 15,200 shares during the period. Finally, Walleye Capital LLC acquired a new position in shares of Hyperfine during the 4th quarter worth approximately $212,000. 15.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HYPR shares. BTIG Research assumed coverage on shares of Hyperfine in a report on Wednesday, April 29th. They set a “buy” rating and a $2.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a research note on Friday, July 17th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Hyperfine in a research report on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Hyperfine presently has an average rating of “Hold” and an average target price of $1.78.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.